{"created":"2023-05-18T10:12:03.888955+00:00","id":3930,"links":{},"metadata":{"_buckets":{"deposit":"ff49b127-7e58-4a82-b0b3-032ec78dc623"},"_deposit":{"created_by":5,"id":"3930","owners":[5],"pid":{"revision_id":0,"type":"depid","value":"3930"},"status":"published"},"_oai":{"id":"oai:yamanashi.repo.nii.ac.jp:00003930","sets":["205:357:372"]},"author_link":[],"item_10001_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2005","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"2","bibliographicPageEnd":"90","bibliographicPageStart":"83","bibliographicVolumeNumber":"18","bibliographic_titles":[{"bibliographic_title":"山梨肺癌研究会会誌","bibliographic_titleLang":"ja"},{"bibliographic_title":"Journal of the Yamanashi Society for Lung Cancer","bibliographic_titleLang":"en"}]}]},"item_10001_creator_2":{"attribute_name":"著者名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"西川, 圭一","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"山口, 弘","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"山家, 理司","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"久木山, 清貴","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"菱山, 千祐","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"大木, 善之助","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"小澤, 克良","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"宮木, 順也","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"成宮, 賢行","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"金澤, 正樹","creatorNameLang":"ja"}]},{"creatorNames":[{"creatorName":"石原, 裕","creatorNameLang":"ja"}]}]},"item_10001_description_5":{"attribute_name":"内容","attribute_value_mlt":[{"subitem_description":"【目的】進行非小細胞肺癌(NSCLC)に対するジェムシタビン(GEM)+カルボプラチン(CBDCA)療法の推奨用量を決定し、推奨用量における安全性及び抗腫瘍効果を検討した。【対象と方法】対象は病理学的診断の得られた臨床病期ⅢB/Ⅳ期のNSCLC初回治療症例で、performance status(PS)0-2、年齢20-75歳、臓器機能の保たれている症例とした。第Ⅰ相試験はGEMは1,000mg/m2(day 1,8)に固定、CBDCA(day 8)のAUCをレベル1は4、レベル2は5、レベル3は6とし、4週毎に2コース行い効果判定を行った。【結果】Dose limiting toxicity(DLT)はレベル1でgrade 4の血小板減少を1例認めたのみであった。この結果からCBDCAのAUCF 6を推奨投与量とし、第Ⅱ相試験を行った(primary endpoint:抗腫瘍効果、毒性、secondary endpoint:生存期間)。なお2コース目以降を原則通院治療としたため、毒性に応じて薬剤の減量基準を設けた。第Ⅱ相試験では27例が登録され、PS 0が24例(88.9%)、PS 1が3例(11.1%)とPS良好な症例が大多数であった。治療成蹟は奏効率33.3%、平均生存期間は54.0週であった。血液学的毒性は、grade3・/4の血小板減少が22.2%(grade 4なし)、grade 3/4の好中球減少が33.3%であり、また非血液学的毒性はわずかであった。【結静】GEM+CBDCA療法は忍容性が高く、良好な抗腫瘍効果が得られ、また外来治療も十分に可能であり、PS良好な進行非小細胞肺癌において極めて有用な治療法と考えられた。","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10001_identifier_registration":{"attribute_name":"ID登録","attribute_value_mlt":[{"subitem_identifier_reg_text":"10.34429/00003923","subitem_identifier_reg_type":"JaLC"}]},"item_10001_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"山梨肺癌研究会","subitem_publisher_language":"ja"}]},"item_10001_source_id_11":{"attribute_name":"NCID","attribute_value_mlt":[{"subitem_source_identifier":"AN10355815","subitem_source_identifier_type":"NCID"}]},"item_10001_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1341-7053","subitem_source_identifier_type":"ISSN"}]},"item_10001_text_4":{"attribute_name":"タイトルヨミ","attribute_value_mlt":[{"subitem_text_language":"ja-Kana","subitem_text_value":"シンコウ ヒショウサイボウ ハイガン ニ タイスル ジェムシタビン ト カルボプラチン ヘイヨウ カガク リョウホウ ノ リンショウ ダイ 1 2 ソウシケン"}]},"item_10001_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2020-02-27"}],"displaytype":"detail","filename":"KJ00004303754.pdf","filesize":[{"value":"620.7 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"KJ00004303754.pdf","objectType":"fulltext","url":"https://yamanashi.repo.nii.ac.jp/record/3930/files/KJ00004303754.pdf"},"version_id":"f40556a2-2a9b-4633-bcbf-a8d802d4abb5"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"非小細胞肺癌","subitem_subject_language":"ja"},{"subitem_subject":"化学療法","subitem_subject_language":"ja"},{"subitem_subject":"ジェムシタビン","subitem_subject_language":"ja"},{"subitem_subject":"カルボプラチン","subitem_subject_language":"ja"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"進行非小細胞肺癌に対するジェムシタビンとカルボプラチン併用化学療法の臨床第I/II相試験","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"進行非小細胞肺癌に対するジェムシタビンとカルボプラチン併用化学療法の臨床第I/II相試験","subitem_title_language":"ja"}]},"item_type_id":"10001","owner":"5","path":["372"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2009-03-13"},"publish_date":"2009-03-13","publish_status":"0","recid":"3930","relation_version_is_last":true,"title":["進行非小細胞肺癌に対するジェムシタビンとカルボプラチン併用化学療法の臨床第I/II相試験"],"weko_creator_id":"5","weko_shared_id":-1},"updated":"2023-10-11T07:51:33.647970+00:00"}